Vigil Neuroscience (VIGL) shares surged over 26% in recent Thursday trading following positive results from a Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease, supporting its advancement to a mid-stage clinical trial.
The initial Phase 1 study demonstrated a favorable safety and tolerability profile for VG-3927 across all subjects, including elderly participants.
VG-3927 achieved a dose-dependent reduction of soluble TREM2 levels in cerebrospinal fluid by about 50% and showed activation of the TREM2 receptor, which is believed to support brain health through microglial activity.
Based on these findings, Vigil said it plans to advance a once-daily oral dose of 25 milligrams into a Phase 2 trial, expected to begin in Q3.
Price: 2.56, Change: +0.53, Percent Change: +26.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.